IL18BP

Across TCGA pan-cancer cohorts, IL18BP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IL18BP data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IL18BP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IL18BP expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where IL18BP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	1.000	0.413	.011	18	view →
LUAD	OS	Quartile	All	0.361	0.916	.001	14	view →
PDAC	OS	Median	All	0.623	0.368	.002	14	view →
CCRCC	OS	Median	III,IV	0.533	0.815	.030	8	view →
LSCC	DFS	Median	All	0.929	0.567	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IL18BP–HNSC (DFS)

Open the HNSC breakdown →